Conventional chemotherapy circulates through the body, while only part of an administered dose may reach a tumor. Exposure in healthy tissues can cause toxic side effects and limit the dose that can be given. Targeted nanomedicines address this challenge by placing drug molecules in nanoscale carriers that can change their distribution, circulation time and release behavior. For technical decision-makers, the key point is that a carrier is not simply a container: its material and structure influence how a medicine behaves in the body.
Why use nanocarriers for cancer drugs?
Drug targeting can take several forms. A therapeutic molecule may act directly on a disease biomarker; an antibody or peptide may guide a drug through a direct attachment; or a carrier may transport drug molecules toward diseased tissue. Nanomedicines use the third approach, sometimes alongside a targeting agent attached to the particle surface.
Encapsulation or association with a carrier can improve a drug’s solubility or stability and alter its biodistribution and bioavailability. These changes may help concentrate drug exposure in diseased tissue, reduce exposure elsewhere, or modify the release profile. The intended outcome is a more favorable balance between therapeutic effect and toxicity—not an automatic guarantee that a treatment will be more effective or safer.
How passive cancer targeting works
After intravenous administration, free drug molecules can move through small spaces between blood-vessel endothelial cells and distribute widely. Nanocarriers are larger and may remain in circulation longer, particularly when their surfaces are modified to reduce recognition and clearance by the body.
Tumor and inflammatory tissues can have more permeable blood vessels than healthy tissues. Nanoparticles may pass through these openings and remain in the affected area, a process known as the enhanced permeability and retention (EPR) effect. The carrier can then release its drug cargo. This is passive targeting: it relies on differences in tissue vasculature and particle behavior rather than a specific binding interaction.
Active targeting is a separate strategy. A surface-bound ligand, such as an antibody or peptide, can interact with a marker associated with the intended tissue. The review distinguishes this mechanism from passive targeting; the two approaches can also be combined. In either case, particle size, stability in circulation, drug retention and release are central design considerations.
Carrier choice shapes drug behavior
Nanocarriers differ in composition, structure and the way they hold and release a drug. Their benefits and limitations depend on the formulation and intended use.
- Liposomes are vesicles with a lipid bilayer surrounding an aqueous core. They can carry different types of drug cargo and have been used to change drug retention and tissue distribution. Their stability can be affected by lipid oxidation or hydrolysis, as well as particle aggregation during storage.
- Micelles form when amphiphilic molecules assemble in water. Their hydrophobic interior can carry poorly water-soluble drugs. The critical micelle concentration matters: dilution can destabilize micelles and release the drug, so low critical micelle concentrations are generally preferred.
- Lipid nanoparticles, including solid lipid nanoparticles and nanostructured lipid carriers, can accommodate drugs within a lipid matrix or core. Drug location affects release: surface-associated drug may be released more rapidly, while drug held inside may be released more slowly. Drug loading and long-term leakage are among the design challenges.
- Polymeric nanoparticles can take the form of a drug-containing matrix or a polymer shell around a core. Release may occur through diffusion, erosion, degradation or, in some designs, response to a stimulus such as pH, heat or light. Polymer choice and production method influence their properties.
- Drug nanocrystals consist of drug material in nanoscale crystals rather than drug enclosed in a carrier. Their greater surface area can increase dissolution rate, but the drug must dissolve at the target site to become pharmacologically available.
Dendrimers, nanoemulsions, carbon-based particles, quantum dots and metallic nanoparticles represent other approaches. Their potential uses vary, and each raises distinct considerations, including toxicity, stability, drug loading and the difficulty of producing consistent materials at scale.
PEGylation and circulation time
In the bloodstream, foreign particles may be recognized by opsonins and removed by macrophages. PEGylation—coating a particle with polyethylene glycol—can reduce this recognition. PEG attracts a layer of water at the particle surface, helping shield it from opsonization. The degree and distribution of surface coverage matter: sparse or incomplete coverage may offer less protection than a dense coating.
Longer circulation can increase the opportunity for a nanomedicine to reach diseased tissue. But circulation time is only one part of performance. Drug release, tissue distribution, carrier degradation and the possibility of accumulation outside the target all need to be considered.
Clinical performance depends on pharmacokinetics
When a drug is placed in a carrier, its pharmacokinetic and pharmacodynamic behavior can differ from that of the free drug. Relevant measures include clearance, distribution volume, half-life and exposure over time. For example, liposomal formulations of some chemotherapy drugs have been associated with longer retention or altered distribution, while albumin-bound paclitaxel and polymer-conjugated camptothecin illustrate how carriers can change drug delivery and exposure.
These examples do not mean every carrier improves every outcome. A formulation may change toxicity, dose delivery or drug exposure without producing the same effect across all cancers or patients. Clinical assessment must therefore consider the specific drug, carrier, indication and evidence available for that formulation.
Practical implications for formulation and development
Developing a nanomedicine requires balancing interdependent properties. A particle must carry an appropriate amount of drug, remain sufficiently stable during circulation, release its cargo at a useful rate and avoid unacceptable effects in healthy tissue. Manufacturing and storage add further constraints: some carriers can aggregate, leak drug or be difficult to produce at larger scale. For engineers and technical teams involved in development, these trade-offs make material selection and process control integral to the final drug product.
The practical promise of targeted nanomedicines lies in changing where and how long a cancer drug is available—not merely making the drug smaller. Understanding the targeting mechanism, carrier structure, surface design and pharmacokinetic profile helps clarify what a formulation can realistically achieve. Those properties, together with safety and production considerations, should guide decisions about its clinical role.